Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chugai Pharmaceutical has entered into an agreement with Taisho Pharmaceutical to co-develop and co-market ED-71, an activated vitamin D derivative, which Chugai is currently developing in Japan for the treatment of osteoporosis.
Subscribe to our email newsletter
Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical, a subsidiary of Taisho. Chugai will receive an upfront fee and milestone payments from Taisho.
Through the joint effort to develop and market ED-71, Chugai and Taisho hope to provide one of the options of osteoporosis treatment to as many patients as possible.